

CSL
2024 Research Acceleration Initiative

November 2023

Research External Innovation Europe

Legal Notice

The information provided in this document is provided “as is” without warranty of any kind; either express or implied and is intended for informational purposes only. The information contained herein is subject to change at any time without notice.

In no event shall CSL Limited be liable for any direct, indirect, special or consequential damages or any damages whatsoever resulting from loss of use, data, or profits arising out of or in connection with the use of this information.

AGENDA

Overview of CSL

CSL's core Therapeutic Areas

CSL Research Acceleration Initiative

Areas of interest for collaboration

Benefits of collaborating with CSL

Questions

Overview of CSL

Our Businesses

CSL Behring

Biotherapies & Rare Disease

CSL Seqirus

Vaccines

CSL Vifor

Iron Deficiency & Nephrology

Driven by Our Promise

* CSL will follow the required legal processes of formally changing the names for Vifor Pharma and Seqirus entities in due course.

CSL at a Glance

40+

Countries of operations around the world

US$13.3

Billion in annual revenue

US$5.1

Billion in R&D investments in the last 5 years to advance product pipeline

32,000+

Employees around the world

2000+

R&D employees

340+

Plasma collection centres across China, Europe and North America

Top 25 Biotech Companies of 2023

GEN Genetic Engineering & Biotechnology News

Rank	Company	Ticker Symbol	Market Cap (US$ Billion)
1	Novo Nordisk	NOVO-B (CPH)	371.64
2	Thermo Fisher Scientific	TMO (NASD)	210.51
3	Amgen	AMGN (NASD)	126.31
4	**CSL Ltd**	**CSL (ASX)**	**101.4 B**
5	Gilead Sciences Inc	GILD (NASD)	99.98
6	Vertex Pharmaceuticals	VRTX (NASD)	88.83
7	Regeneron Pharmaceuticals	REGN (NASD)	87.64
8	Daiichi Sankyo	4568 (TOKYO SE)	69.55
9	Moderna	MRAN (NASD)	50.56
10	Jiangsu Hengrui Medicine Co Ltd	600276 (SHSE)	46.31
11	Chugai Pharmaceutical	4519 (TOKYO SE)	45.86
12	Biogen	BIIB (NASD)	44.69
13	Lonza	LONN (SWX)	44.33
14	Samsung Biologics	207940 (KRX KE)	44.12
15	Agilent Technologies	A (NYSE)	40.08
16	Seagan	SGEN (NASD)	37.5
17	Illumina	ILMN (NASD)	30.79
18	WuXi App Tec	603259 (SSEC)	29.33
19	Sun Pharmaceutical Industries	SUNPHARMA (NSE)	28.73
20	BeiGene	BGNE (NASD);06160 (HKE); 688235 (STAR SSEC)	27.50

https://www.genengnews.com/industry-news/top-25-biotech-companies-of-2023/

CSL's Key Global R&D Locations

King of Prussia | US
Kankakee | US
Pasadena | US
Waltham | US
Summit | US
Holly Springs | US

Amsterdam | Netherlands
Liverpool | UK
Marburg | Germany
London | UK
Siena | Italy
Bern | Switzerland
Zurich | Switzerland
Palma de Mallorca | Spain

Tokyo | Japan
Wuhan | China
Shanghai | China

Melbourne | Australia

Expanding footprint and alliances in leading biomedical locations centres

>2,000+
employees in 10 countries

Research Acceleration Initiative

CSL's Research Acceleration Initiative

Objective: to build relationships with entrepreneurial researchers and fastrack discovery of innovative medicines that address unmet needs

Why? Early collaborations with high quality academic partners are key to building a sustainable pipeline

CSL's RAI provides a differentiated approach to partnering:

- ✓ Up to USD $400,000 funding over 2 years
- ✓ CSL scientific champion assigned to each project
- ✓ Focused on early-stage projects
- ✓ Simple and fast 300-word initial application
- ✓ Clear and transparent timelines



CSL has invested in 30+ RAI partnerships since 2019

*"We had a **stellar experience participating in the CSL RAI process**. The information material, informational webinars, and access to the program team for Q&A was well received by our faculty"*

RAI 2023 participant
University of Pittsburgh

*"It has been a great pleasure to collaborate with our colleagues at CSL. The Research Acceleration Initiative (RAI) is an **outstanding platform that helps bridge the academic world with industry**."*

RAI 2021 awardee
Justus-Liebig-Universität Giessen

*"**CSL Behring has proven to be an exceptional collaborator**, fostering a scientifically focused partnership marked by open scientific exchange and generosity. Their extensive research expertise has consistently enriched our collaborative efforts"*

RAI 2021 awardee
Klinikum der Universität München (KUM)

*"...the webinar session was very useful because it **clearly indicated which areas CSL was interested in funding**, thereby allowing me to focus my thoughts on them."*

RAI 2022 awardee
Nanyang Technological University

*"Peerless experience – **timely, transparent, actionable communication**."*

RAI 2023 participant
University of British Columbia

"...the opportunity to address **feedback from CSL and to refine the project was particularly valuable**"

RAI 2023 participant
The University of Adelaide

*"Well-designed, easy and clear process. **Highly engaged and highly responsive to all questions** and provided well-contemplated and customised feedback."*

RAI 2023 participant
University of Toronto

*"The types of projects CSL were looking for was made very clear, the process of submitting an application was easy and **did not require excessive time or effort**."*

RAI 2023 participant
Auckland UniServices Ltd

SEVEN NEW CSL RESEARCH

7

ACCELERATION INITIATIVE AWARDEES ANNOUNCED

Dr Laurent Martinez
Institute of Cardiovascular and Metabolic Diseases (I2MC), IHU HealthAge, INSERM / University of Toulouse, France

Prof. Delphine Borgel
INSERM - APHP - Université Paris SACLAY, France

Prof. Denis Vivien
INSERM / Caen Normandie University Hospital, France

Research Director Benoit Salomon
INSERM / University of Toulouse, France

Assoc Prof. Tan Meng How
Nanyang Technological University, Singapore

Prof. Elisa Laurenti
University of Cambridge, United Kingdom

Prof. Leon Schulte
Philipps-Universität Marburg, Germany

Driven by Our Promise

CSL

CSL 2024 Research Acceleration Initiative Process



No obligation for registered organizations to submit applications

No limitation on number of abstracts each registered organization can submit

Agreement Guidance

Separate collaboration agreements will be negotiated for each project which reflect the nature of the project, nature of funding and support, and the contributions of both parties

Under these negotiated agreements, CSL will be granted certain rights of interest to the program results for further R&D and/or commercialization

Collaboration agreements will typically include the following terms (although CSL may propose other conditions depending on the nature of the project):

- *Research organization will generally own results arising under the project*
  - CSL would typically own any results which relate to proprietary CSL products or materials contributed to the project or may seek joint-ownership of results to which it has made a significant contribution (e.g. protein or antibody discovery and engineering activities).
  - The RAI is designed to accelerate the translation of novel discoveries made by research scientists – for proposals outside this scope, we may propose that projects be progressed outside the RAI
- *CSL will be granted an exclusive option to negotiate an exclusive, worldwide licence*
- *CSL supports publication of research outcomes*

Further details on agreement terms can be provided on request

Eligibility

To be eligible to apply, researchers/clinicians must satisfy the following 2 conditions:

1. Be employed by a research organization registered to participate in the 2024 Research Acceleration Initiative

2. Submit a 300-word online abstract that is aligned with CSL's Therapeutic Areas and scientific Platforms:



Specific indications of focus within each TA are provided on slides 28-35.

Abstract submission via online portal

Step 1/2 - Lead Investigator Information

Applications for the 2023 CSL Research Acceleration Initiative open 3rd January 2023 and close 23rd February 2023. Applications received outside these dates (before or after) will not be reviewed.

Fields with * are mandatory

First Name *

Salutation

Last Name *

Job Title *

Organization *

Phone

Email *

Confirm Email *

Address

City

Zip/Postcode

Country *

Geographical region *

Are you an existing collaborator, or have you previously collaborated with CSL (including CSL Behring, CSL Seqirus or CSL Vifor)?

◯ Yes ◯ No

CONTINUE

Step 2/2 - Describe your opportunity and confirm submission

Please describe and categorize your opportunity.

Fields with * are mandatory

Proposal Title *

Primary Therapeutic Area *

Not specific to a Therapeutic Area (e.g. platform technology)

Secondary Therapeutic Area

Not specific to a Therapeutic Area (e.g. platform technology)

Indications *

Modality *

Cell therapy	Extracellular vesicles	Gene therapy
Oligonucleotide (siRNA, asRNA, ncRNA)	Peptide	Plasma
Recombinant (incl. antibodies)	Small molecule	Other modality

Opportunity Type *

Biomarker	New use for CSL product or pipeline candidate	Novel target or therapeutic candidate
Research Tool	Target Discovery	
Vaccines – mRNA/lipid nanoparticle platform improvements	Vaccines – influenza virus antigen purity/yield enhancements	
Vaccines – utilizing MF59® adjuvant	Other	

Project Description (max. 300 words) *

Example of what to include in Project Description: "We have discovered a novel target expressed on X cells. We have generated data in X assay(s) and/or X model(s). We have shown the mechanism of action is mediated via X pathway(s). Inhibition of this target could be used to treat X indication(s). This novel strategy could address an important unmet need for patients and be superior to standard of care and other therapeutics in development for reasons X, X and X."

I have read the privacy policy and agree with it. Read more... *

I hereby confirm that my submission does not contain any confidential information. *

I'm not a robot

BACK SUBMIT

Submission T&Cs on last slide

What is involved for participating research organizations?

Abstracts

- Internal promotion of initiative (*CSL to provide flyer)*
- Promotion of CSL information sessions/webinars for interested researchers
- Provide abstract submission portal link to researchers
- Discuss proposals with interested scientists ahead of 300-word abstract submission deadline

Full Application

- Support shortlisted researchers with preparation of full proposal via CSL RAI application form
- Ensure no disclosure of confidential information prior to submission of applications to CSL

Confidential Presentations

- Facilitation of CDA
- Assist with scheduling of confidential presentations to CSL

Funding Outcome

- Contract negotiation
- Preparation of detailed research plan and budget in partnership with CSL

Connect CSL with the appropriate internal contact(s) for each stage of the process

What makes for a competitive proposal?

- ✓ Aligned with our focus areas and modalities (slides 28-35)
- ✓ Project is clearly defined (as opposed to a general overview of the applicant's research interests)
- ✓ Focused on a novel target or therapeutic candidate
- ✓ Clear differentiation of approach from competitors and current standard of care
- ✓ Research team has capacity and expertise to complete the bulk of the experimental work over the course of the program (with CSL guidance and support)
- ✓ If third party IP is required, ensure your research organization has secured all necessary rights to grant CSL an exclusive option to negotiate an exclusive, worldwide licence

Examples of activities funded in previous RAI partnerships

- ✓ Human target validation and translational studies using patient samples
- ✓ Mechanism of action studies for therapeutic candidates
- ✓ Benchmarking to provide proof-of-concept for the differentiation of novel therapeutics to standard-of-care or competing therapeutics in development
- ✓ Target validation using genetic knock-out/knock-in or tool compounds in preclinical disease models
- ✓ Characterization of therapeutic candidates (e.g. affinity, potency, selectivity, and developability)

Benefits of collaborating with CSL



Benefits of CSL's Research Acceleration Initiative

Collaborate
with one of the world's leading biotech companies

Publish with CSL
200+ publications with our collaborators since 2020

Funding
of up to $400,000 USD over 2 years

Access expertise
CSL scientific champion assigned to provide you with industry guidance

Recognition
Awardees may use the title "CSL Research Acceleration Initiative Fellow"

Accelerate
the translation of your research into new therapies

Access global capabilities
in R&D, clinical, intellectual property, manufacturing and commercial

Demonstrate impact
of your research to funding bodies via industry collaboration

Capabilities from Discovery to Patients



Antibody Discovery and Protein Engineering

In vitro pharmacology



Animal Models of Disease

Toxicology & Product Development

Patients

R&D CAPABILITIES — **CLINICAL CAPABILITIES**

Protein production and purification



Analytical Biochemistry

Translational Medicine & Data Science

Phase I-III/Launch Manufacturing

CSL's core Therapeutic Areas



CSL's Core Therapeutic Areas & Platforms



CSL R&D Portfolio – FY24



Product and pipeline highlights

Privigen® (10% intravenous Ig)
Primary immunodeficiencies (PID), Secondary Immune Deficiency (SID)*, Chronic inflammatory demyelinating polyneuropathy (CIDP)

Hizentra® (20% subcutaneous Ig)
PID, CIDP, SID*
Dermatomyositis (DM), Ph III

Haegarda® (C1 Esterase Inhibitor)
Hereditary angioedema

Garadacimab (Anti-FXIIa mAb)
Hereditary angioedema, Ph III

CSL324 (Anti-G-CSFR mAb)
Hidradenitis suppurativa (HS), Ph I

Idelvion® (Recombinant FIX-FP)
Hemophilia B

Hemgenix® (AAV FIX gene therapy)
Hemophilia B

Afstyla® (Recombinant FVIII)
Hemophilia A

Kcentra® (Prothrombin complex concentrate)
Urgent warfarin reversal

Vamifeport (Oral ferroportin inhibitor)
Sickle cell disease, Ph IIa

CSL889 (Hemopexin)
Sickle cell disease, Ph I

CSL888 (Haptoglobin)
Sub-arachnoid hemorrhage, preclinical development

ZEMAIRA®/RESPREEZA®
(Alpha 1 Antitrypsin)

Garadacimab (Anti-FXIIa mAb)
Idiopathic Pulmonary Fibrosis, Ph IIa

CSL311 (Anti-β-common mAb)
Airways inflammation, Ph I

CSL787 (Nebulized Ig)
Respiratory infections, Ph I



CSL112 (ApoA-1)
Acute coronary syndrome, Ph III

CSL300 (Anti-IL-6 mAb)
End stage kidney disease
Ph IIb

FLUAD Quadrivalent
Adjuvanted Influenza Vaccine

FLUCELVAX Quadrivalent
Cell-based Influenza Vaccine

Adjuvanted Cell Culture Influenza Vaccine (aQIVc), Ph II

sa-mRNA Influenza Vaccine, PC

ARCT-154 COVID-19 Vaccine, Ph III

CSL964 (Alpha 1 Antitrypsin)
Graft versus host disease, Ph III

Clazakizumab (Anti-IL-6 mAb)
Antibody mediated rejection, Ph III

CSL040 (Novel Complement Inhibitor), Ph I

*ex-USA

Our full pipeline can be viewed here

Areas of interest for collaboration



*Areas **not** of interest*

- *Oncology (including hematological malignancies)*
- *Medical devices or diagnostics*
- *Small molecule approaches*

Immunology

Core interests for early stage partnering

Novel targets or best-in-class biologic therapeutics addressing:

1. B cell and plasma cell depletion or inhibition
2. T cell modulation, immune checkpoint agonism or co-stimulatory antagonism, regulatory T cell stimulation or tolerance
3. Modulation of cytokines, chemokines and immune-super family members (e.g., TNF, IL-1, other) , particularly approaches enabling multi-pathway inhibition
4. Depletion/modulation of innate immune effector cells

Autoimmune diseases:

Inflammatory Idiopathic Myopathies including Dermatomyositis, Primary Sjögren's Syndrome, Pemphigus Vulgaris, Bullous Pemphigoid, Small Fiber Neuropathy, ANCA-Associated Vasculitis and Autoimmune Hepatitis

Not of interest:

Target discovery campaigns or platforms, intracellular targets, complement inhibition

Hematology

Core interests for early stage partnering

Acute hemorrhage control and hemorrhagic stroke

1. Novel biologic therapies to treat and prevent acute hemorrhage (e.g. intracerebral hemorrhage (ICH), reversal of anti-coagulation/anti-platelet associated bleeding)
2. Novel biologic targets and therapies for the treatment of secondary brain injury in subarachnoid hemorrhage and ICH
3. Omics approaches for patient stratification and drug discovery

Acute thrombotic conditions (macro- and micro-circulation)

1. Novel biologic therapies for targeted fibrinolysis/thrombolysis in acute thrombosis (ischemic stroke, pulmonary embolism)
2. Novel biologic therapies to treat and prevent microvascular thrombosis and endotheliopathies (e.g. TMAs, APS and DIC).

Benign hematology adjacencies*

1. Novel biologic therapies for the treatment of anemias
2. Novel biologic therapies to treat bone marrow disorders

* excluding SCD

Respiratory

Core interests for early stage partnering

Idiopathic pulmonary fibrosis (IPF), pulmonary sarcoidosis and progressive pulmonary fibrosis (PPF)

1. Novel biologic therapies or target proposals derived from translational or biobank cohorts
2. Therapies targeted at reversing remodelling of fibrotic lung tissue
3. Multiomics-based approaches to target discovery

Community acquired pneumonia (CAP)-associated complications

(Acute Respiratory Distress Syndrome (ARDS), Sepsis, Acute kidney injury)

1. Novel biologic therapies or target proposals derived from translational or biobank cohorts
2. In Silico approaches for patient stratification to delineate CAP patients at risk for ARDS/Sepsis/AKI



Cardiovascular and Metabolic

Core interests for early stage partnering

Major Adverse Cardiovascular Event (MACE) prevention
Atherosclerotic plaque stabilization in severe disease

Rare lipid disorders
Novel targets or biologic therapies (including gene therapies) for rare lipid disorders e.g. homozygous familial hypercholesterolemia

Myocarditis
Novel targets or biologic therapies for myocarditis
Biomarker approaches for patient stratification

Inflammatory cardiomyopathies
Novel targets or biologic therapies for inflammatory cardiomyopathies



Nephrology and Transplant

Core interests for early stage partnering

Acute and chronic solid organ transplant rejection (kidney/lung) therapies

Novel biologic therapies or targets to prevent or treat acute and chronic solid organ transplant rejection of the kidney and lung

Chronic graft versus host disease (GvHD)

Novel biologic therapies for the treatment and prevention of chronic GvHD

Tolerance for organ transplant rejection

Novel biologic therapies for the induction of tolerance to prevent or treat organ transplant rejection



Vaccines

Core interests for early stage partnering

Respiratory vaccines

1. New antigenic targets (epitopes or combinations)
2. Methods (e.g. AI/machine learning) to predict respiratory viral evolution/pathogenicity to inform vaccine development

New vaccine targets

Development of novel targets/approaches for any disease

RNA delivery and therapeutics

1. RNA delivery, enhanced stability, route of administration and/or expression strategies
2. mRNA-encoded protein therapies encompassing cellular targeting technologies

Immune mechanisms

Understanding innate and adaptive responses to vaccines



Cell & Gene Therapy

Core interests for early stage partnering

Gene editing / genomics

1. Improve insertional editing efficiencies *in vivo*
2. Genetic elements enhancing regulation of cells of the immune system (e.g. promoters and enhancers)

In vivo Delivery

1. Delivering nucleic acid templates for insertional gene editing
2. Targeting moiety for HSCs

GT safety

Technologies that minimize SAEs from insertional gene editing

Areas not of interest

- Oncology (including hematological malignancies)
- Ex vivo cell therapy



Plasma Protein Research

Core interests for early stage partnering

Novel plasma therapeutic candidates

1. All diseases considered. Candidates aligned with CSL's therapeutic areas will be prioritized
2. CSL can provide native human plasma proteins (≥ µg/L plasma concentration) for preclinical proof-of-concept studies

Novel association of plasma protein function with disease

1. Based on healthy and patient clinical data sets, or
2. Access to patient data sets with corresponding clinical data to enable association studies to be performed

Novel methods for plasma protein purification

Protein purification systems capable of targeted purification from plasma with high purity at research scale (methods translatable to manufacturing scale will be prioritized)

Checklist for 2024 Research Acceleration Initiative

- Register your research organization by 15th Dec 2023 by emailing RAI@csl.com.au (NB: 2023 participants are automatically re-enrolled)
- Update your organization's primary contact details if required
- CSL will provide flyer with primary contact details for promotion within your research organizations
- CSL will provide the link to the online abstract submission portal
- CSL will provide you with invitations to information webinars to share with interested researchers – webinars will be held in Feb 2024
- Online portal opens for abstract submissions by researchers on 2nd Jan 2024 and closes on 27th Feb 2024

Questions

THANK YOU

Dr Nathan Lawless
Director,
Research Innovation Europe

nathan.lawless@cslbehring.com

Dr Marco Cavallari
Senior *Manager, Research Innovation Europe*

marco.cavallari@cslbehring.com

Dr Naja Nyffenegger
Senior *Manager, Research Innovation Europe*

naja.nyffenegger@viforpharma.com

RAI@cslbehring.com

csl.com/csl-rai



Terms and Conditions for Research Acceleration Initiative Portal ("RAI Portal")

1. This RAI Portal is an online portal operated by CSL Innovation Pty Ltd ("CSL") for the purpose of allowing individuals to submit scientific proposals for consideration by CSL for its Research Acceleration Initiative program. By using this website and the RAI Portal, and by providing your submission and personal information to CSL, you are agreeing to abide by these terms and conditions.

2. You acknowledge and agree that CSL has no obligations of confidentiality or non-use in relation to the submission provided. You warrant that your submission does not contain confidential information of any kind. Further, you acknowledge that notwithstanding the existence of any confidentiality agreements previously entered into between you and CSL, the terms of such agreements will not apply with respect to any information submitted by you through the RAI Portal.

3. You further represent and warrant that:

- a. you have the right and authorization (including where relevant after consultation with all relevant commercialization or technology transfer offices) to submit an application to the RAI Portal and to accept the terms and conditions set out herein;
- b. you are an employee or are otherwise affiliated with a registered organization authorized by CSL to submit an application to the RAI Portal; and
- c. to the best of your knowledge and without making any further enquiries, the information provided in your submission (and CSL's use of that information in connection with the Research Acceleration Initiative program) shall not infringe on the intellectual property rights of any third party, including your current or former employer, university, public research institute or other registered organization.

4. CSL may disclose personal information collected in connection with your use of this website or the RAI Portal to your employer, university, public research institute or other registered organization (if applicable) as at the time your application was submitted, solely for the purpose of reviewing and determining your application. CSL will ensure that any personal information collected, used or disclosed in connection with your use of this website or the RAI Portal is handled in accordance with all relevant privacy legislation and with CSL’s privacy policy, a copy of which is available at https://www.csl.com/privacy-policy.

5. CSL is under no obligation to respond to any individual application submitted to the RAI Portal, and may in its sole discretion choose not to progress an application further for any reason without any further communication with you.